Stay updated with breaking news from Alan Tribe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Insiders appear to have a vested interest in PYC Therapeutics' growth, as seen by their sizeable ownership...
Tim Boreham highlights how PYC Therapeutics' gene therapy can address a plethora of genetic afflictions
Despite higher average salaries thanks to the mining sector, many would be surprised to hear Perth remains the most affordable capital city.
Share this article Share this article NEW YORK and PERTH, Australia, April 30, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones. "PYC has had an exciting quarter of progress against our Company objectives. We have achieved continued validation of our PPMO technology in our lead candidate VP-001 for retinitis ...